upadacitinib
-
Favorable responses to upadacitinib, a JAK1 inhibitor, in [LC] with predominant neuropsychiatric symptoms: case reports [...], 2025, Jyonouchi et al
Favorable responses to upadacitinib, a JAK1 inhibitor, in long COVID patients with predominant neuropsychiatric symptoms: case reports in 2 autistic patients and one typically developing patient Harumi Jyonouchi, Jeffery Kornitzer, Lee Geng [Line breaks added] Abstract The long-term impact of...- forestglip
- Thread
- autism jak inhibitors jak1 long covid neuropsychiatric disorders upadacitinib
- Replies: 2
- Forum: Long Covid research
-
Potential Mechanism of Fatigue Induction and Its Management by JAK Inhibitors in Inflammatory Rheumatic Diseases 2024, Anna Felis-Giemza et al
Open Access: Full article: Potential Mechanism of Fatigue Induction and Its Management by JAK Inhibitors in Inflammatory Rheumatic Diseases (tandfonline.com) Abstract It is well known that fatigue is a highly disabling symptom commonly observed in inflammatory rheumatic diseases (IRDs)...- pooriepoor91
- Thread
- fatigue jak inhibitors patient reported outcome measures tofacitinib upadacitinib
- Replies: 1
- Forum: 'Conditions related to ME/CFS' news and research